FLRT1: A Potential Drug Target Or Biomarker (G23769)

Target Name: FLRT1

NCBI ID: G23769

FLRT1

Other Name(s): Fibronectin leucine rich transmembrane protein 1, transcript variant X1 | Leucine-rich repeat transmembrane protein FLRT1 | FLRT1 variant X1 | SPG68 | fibronectin leucine rich transmembrane protein 1 | FLRT1_HUMAN | Fibronectin leucine rich transmembrane protein 1 | fibronectin-like domain-containing leucine-rich transmembrane protein 1 | Leucine-rich repeat transmembrane protein FLRT1 (isoform X1) | Fibronectin leucine rich transmembrane protein 1, transcript variant 1 | Fibronectin-like domain-containing leucine-rich transmembrane protein 1 | FLRT1 variant 1

FLRT1: A Potential Drug Target Or Biomarker

FLRT1 (Fibronectin leucine rich transmembrane protein 1, transcript variant X1) is a protein that is expressed in various tissues throughout the body, including connective tissue, heart, kidneys, and liver. It is a member of the fibronectin family, which is a glycoprotein that is involved in cell-cell and cell-extracellular matrix adhesion, as well as in the regulation of cell growth and differentiation.

FLRT1 is characterized by its unique structure, which consists of a long transmembrane region that is rich in leucineresidues, as well as a short cytoplasmic tail that is involved in its stability and localization to the cell surface. It is also capable of forming inclusion complexes with other proteins, such as actinin and vimentin, which are involved in cell-cell adhesion and cytoskeletal organization.

FLRT1 has been shown to play a role in a variety of physiological processes, including cell migration, tissue repair, and cell signaling. For example, it has been shown to be involved in the regulation of T cell development and activation, as well as in the development of cancer. It has also been shown to be involved in the regulation of angiogenesis, the formation of new blood vessels, and in the regulation of vascular permeability.

Due to its unique structure and its involvement in various physiological processes, FLRT1 has potential as a drug target or biomarker. For example, studies have shown that FLRT1 can be targeted with small molecules, such as inhibitors of its signaling pathway, to inhibit its function in cell adhesion and migration. Additionally, its role in regulation of angiogenesis and vascular permeability make it a potential target for therapies that aim to improve blood flow and reduce the risk of cardiovascular disease.

FLRT1 is also a potential biomarker for certain diseases, such as cancer, as its expression has been shown to be increased in various types of cancer, including breast, lung, and colon cancer. Additionally, its role in cell signaling and development makes it a potential target for therapies that aim to inhibit its function in cancer cells, such as anti-cancer drugs that target its signaling pathway.

In conclusion, FLRT1 is a protein that has unique structure and functions, and its potential as a drug target or biomarker makes it a promising target for the development of new therapies. Further research is needed to fully understand its role in various physiological processes and its potential as a drug or biomarker.

Protein Name: Fibronectin Leucine Rich Transmembrane Protein 1

Functions: Plays a role in fibroblast growth factor-mediated signaling cascades that lead to the activation of MAP kinases. Promotes neurite outgrowth via FGFR1-mediated activation of downstream MAP kinases. Promotes an increase both in neurite number and in neurite length. May play a role in cell-cell adhesion and cell guidance via its interaction with ADGRL1/LPHN1 and ADGRL3

The "FLRT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FLRT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets